Is eLife a Good Journal? The Publish-Then-Review Experiment Explained

In October 2022, eLife stopped making traditional accept/reject decisions. Under the new model:

1. You submit a paper

1. Editors decide whether the submission should proceed to peer review

1. If selected, the paper is peer reviewed and then published as a "Reviewed Preprint" with a DOI, public reviews, and an eLife Assessment

1. Reviewers assess it publicly, their reviews and ratings are published alongside the paper

1. You can revise based on reviews; the revised version is also published

1. There is no accept or reject. The paper stays published regardless of what reviewers say

This is fundamentally different from every other major journal. The result: eLife publishes more papers than before (no post-review rejection filter), its measured citation impact fell from 8.7 to a last-published 6.4, and it then became ineligible for a JIF. The community is split on whether this is the future of publishing or an experiment that damaged a formerly elite journal.

The upside:

• No post-review rejection. If eLife sends your paper for review, the reviewed version is published

• Public peer review makes the assessment, strengths, and weaknesses visible with the paper

• Fast publication without months-long review cycles

• The science published in eLife is often excellent, many papers come from leading labs

• The $3,750 fee is waived for authors who cannot afford it, according to eLife

The downside:

• Last published IF fell from 8.7 to 6.4 before eLife became ineligible; matters at institutions using IF thresholds

• "Published in eLife" no longer means "accepted after selective peer review"

• Some hiring committees are confused about what eLife publication means under the new model

• Harsh public reviews are permanently attached to your paper

At progressive institutions that value open science and preprint culture: eLife is well-regarded. The funder backing (HHMI, Wellcome, Max Planck) carries weight.

At traditional institutions using IF thresholds: the new model creates friction. "Published as a Reviewed Preprint" is harder to explain than "Accepted in Journal of Cell Biology."

In preprint-friendly fields (genomics, computational biology, neuroscience): eLife's model feels natural. In fields without preprint norms (clinical medicine, materials science): it feels foreign.

Submit if:

• You value open science and transparent peer review

• Your field has strong preprint culture

• You accept that eLife editors still select which submissions proceed to peer review

• The $3,750 publication fee fits your budget, or you expect to qualify for a waiver

• You're comfortable with public reviews permanently attached to your paper

Think twice if:

• Your institution uses IF thresholds and eLife's last published 6.4 is below the cutoff, with no current IF available

• You need a traditional "accepted" decision for tenure or grants

• Nature Communications JIF 18.1 or EMBO Journal JIF 8.4 is realistic, the IF gap matters

• Your field doesn't understand the publish-then-review model

Before submitting, an eLife vs traditional venue fit check can assess whether your paper's quality matches eLife's standards and whether a traditional venue might serve your career better.

For manuscripts targeting eLife, three patterns generate the most consistent mismatch decisions among the papers we analyze.

Scope misidentification from legacy reputation. eLife's author guidelines specify that submissions must be "of interest to scientists in at least two of eLife's subject areas." We see manuscripts that were clearly targeted at eLife's pre-2022 identity as an elite selective journal, when the journal now operates on a fundamentally different model. The scope check still applies: in-scope papers get published, out-of-scope papers are returned.

Authors who do not update their mental model of eLife are surprised when scope decisions do not match the outcomes they expected at the old journal.

Incomplete internal logic for the new review framework. Under the publish-then-review model, eLife's assessments use specific ratings: "landmark," "fundamental," "important," "valuable," or "useful" for significance, and "exceptional," "compelling," "convincing," "solid," or "incomplete" for evidence strength. We observe that manuscripts with single-model evidence or missing mechanistic controls receive this rating predictably.

A paper that would have been sent for major revision at a traditional journal instead gets published with a permanently attached "incomplete evidence" assessment.

Career-context mismatch. eLife's guidelines do not restrict who can submit, but the career implications of publication differ dramatically by institutional context. We find manuscripts from authors at institutions using JCR JIF thresholds for tenure or promotion, where the eLife model creates genuine complications: no current JCR IF, no traditional acceptance letter, and the need to explain a "Reviewed Preprint" to committees unfamiliar with the model. This is not a scientific problem, but it is a real submission-strategy problem that the journal's own documentation does not fully address.

SciRev author reports on eLife (70 reports, read October 2026) average 11 days for an immediate rejection and 1.6 months for the first review round. A eLife evidence structure and assessment rating check can assess whether your paper's evidence structure would receive a "convincing" or better eLife assessment rating.

eLife's last published JIF was 6.4 (2023 JCR). That continued the fall from 8.713 (2021) through roughly 7.7 (2022 JCR). The 2024 JCR edition and later report no JIF, JCI, or quartile rankings for eLife at all.

The cause is an indexing decision, not just the publishing model. Clarivate paused new eLife content in October 2024, then resumed coverage of only the subset of articles eLife validates through peer review. eLife is therefore partially indexed in ESCI, and partially indexed journals are not eligible to receive a JIF or any other metric that depends on full indexing.

The 6.4 figure is the last value ever published. Do not cite it as a current JCR ranking. If your institution or funder requires a current JCR JIF, eLife cannot provide one.

For the latest editorial policies, see eLife's publishing model page.

Last verified: September 15, 2026 against eLife's current peer-review, submission-fee, and indexing-status pages and the historical JCR record.

ELife eliminated the traditional accept/reject decision after peer review. Since 2023, every article that passes initial editorial screening and peer review is published as a Reviewed Preprint on the eLife website, accompanied by reviewer feedback, an author response, and an eLife Assessment summarizing significance and evidence strength.

This means eLife does not reject papers after peer review. It publishes reviewed papers with transparent quality signals. The eLife Assessment rates findings as "landmark," "fundamental," "important," "valuable," or "useful", and rates evidence strength as "exceptional," "compelling," "convincing," "solid," or "incomplete."

The trade-off: Web of Science paused new eLife content in October 2024. eLife then provided a partial feed so most eligible Versions of Record could remain in the Web of Science Core Collection, but partially indexed journals are not eligible for a JIF. This means eLife papers may not satisfy IF-based evaluation frameworks at some institutions even though most Versions of Record remain discoverable.

Top subject areas: Neuroscience, Cell Biology, Microbiology, Genetics, Immunology. Current publication fee: $3,750, with waivers available according to eLife.

An eLife submission readiness check scores desk-reject risk.